AIM: To assess possible benefits of intravitreal triamcinolone acetonide (IVTA) injection as pretreatment for macular laser photocoagulation (MLP) in patients with diabetic macular edema (DME). METHODS: Published randomized controlled trials (RCTs) concerning MLP with or without IVTA pretreatment for DME were retrieved from databases CNKI, Medline, EMbase, Web of Science, and the Cochrane Library. A Meta-analysis on eligible studies was conducted using RevMan 5.0 software. Two investigators independently assessed the quality of the trials and extracted data. Main outcome measures included the change in best corrected visual acuity (BCVA), difference in central macular thickness (CMT) and adverse events reporting in particular elevated intr...
Objective: To report 3-year outcomes of patients who participated in a randomized trial evaluating 1...
Joint Meeting of the American-Academy-of-Ophthalmology/European-Society-of-Ophthalmology -- 38264 --...
Diabetic macular edema (DME) is the most common cause of vision loss in diabetic patients. Thirty ye...
AIM: To evaluate the clinical effect and safety for diabetic macular edema(DME)with triamcinolone ac...
To compare the efficacy and safety of intravitreal triamcinolone injection to laser photocoagulatio...
Background Diabetic macular oedema is the leading causes of blindness. Laser photocoagulation reduc...
Objective: To compare the efficacy and safety of intravitreal triamcinolone injection to laser phot...
nopathy Study, macular laser photocoagulation has been widely accepted as the treatment of choice fo...
Objective: To compare the efficacy of intravitreal triamcinolone acetonide (IVTA) and IVTA plus macu...
Objective: To evaluate the efficacy and safety of 1 mg and 4 mg doses of preservative-free intravitr...
Background: To compare the effects of laser photocoagulation combined with subtenon injection of tri...
BACKGROUND: To quantify the effect of a combination treatment of intravitreal triamcinolone acetonid...
Background: To quantify the effect of a combination treatment of intravitreal triamcinolone acetonid...
OBJECTIVE: To report 5-year outcomes from a clinical trial of intravitreal triamcinolone acetonide (...
Purpose: To evaluate 14-week effects of intravitreal ranibizumab or triamcinolone in eyes receiving ...
Objective: To report 3-year outcomes of patients who participated in a randomized trial evaluating 1...
Joint Meeting of the American-Academy-of-Ophthalmology/European-Society-of-Ophthalmology -- 38264 --...
Diabetic macular edema (DME) is the most common cause of vision loss in diabetic patients. Thirty ye...
AIM: To evaluate the clinical effect and safety for diabetic macular edema(DME)with triamcinolone ac...
To compare the efficacy and safety of intravitreal triamcinolone injection to laser photocoagulatio...
Background Diabetic macular oedema is the leading causes of blindness. Laser photocoagulation reduc...
Objective: To compare the efficacy and safety of intravitreal triamcinolone injection to laser phot...
nopathy Study, macular laser photocoagulation has been widely accepted as the treatment of choice fo...
Objective: To compare the efficacy of intravitreal triamcinolone acetonide (IVTA) and IVTA plus macu...
Objective: To evaluate the efficacy and safety of 1 mg and 4 mg doses of preservative-free intravitr...
Background: To compare the effects of laser photocoagulation combined with subtenon injection of tri...
BACKGROUND: To quantify the effect of a combination treatment of intravitreal triamcinolone acetonid...
Background: To quantify the effect of a combination treatment of intravitreal triamcinolone acetonid...
OBJECTIVE: To report 5-year outcomes from a clinical trial of intravitreal triamcinolone acetonide (...
Purpose: To evaluate 14-week effects of intravitreal ranibizumab or triamcinolone in eyes receiving ...
Objective: To report 3-year outcomes of patients who participated in a randomized trial evaluating 1...
Joint Meeting of the American-Academy-of-Ophthalmology/European-Society-of-Ophthalmology -- 38264 --...
Diabetic macular edema (DME) is the most common cause of vision loss in diabetic patients. Thirty ye...